Item 8.01 Other Events.

On May 19, 2021, Acceleron Pharma Inc. (the "Company") issued a press release titled "Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On May 19, 2021, the Company also issued a press release titled "Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference." A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

In addition, on May 19, 2021, the Company will host a previously announced conference call and webcast to review the presentations of sotatercept at the American Thoracic Society (ATS) 2021 International Conference. A copy of the slide presentation to be presented during this conference call and webcast is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d)  Exhibits.

 Exhibit Number                                         Description of Exhibit
99.1                      Press release of Acceleron Pharma Inc. dated May 19, 2021
99.2                      Press release of Acceleron Pharma Inc. dated May 19, 2021
99.3                      Slide presentation of Acceleron Pharma Inc. dated May 19, 2021
104                     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses